In the last UK election in 2019, the NHS emerged as a major talking point, as the scale of the country’s support of the service was brought to the fore.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh